| Literature DB >> 27874253 |
Raimundo Romero1, John K Travers2, Emilie Asbury2, Attie Pennybaker2, Laura Chubb3, Ruth Rose3, Nicole P Ehrhart1,3, Matt J Kipper1,2.
Abstract
Critical-sized long bone defects suffer from complications including impaired healing and non-union due to substandard healing and integration of devitalized bone allograft. Removal of the periosteum contributes to the limited healing of bone allografts. Restoring a periosteum on bone allografts may provide improved allograft healing and integration. This article reports a polysaccharide-based tissue engineered periosteum that delivers basic fibroblast growth factor (FGF-2), transforming growth factor-β1 (TGF-β1), and adipose-derived mesenchymal stem cells (ASCs) to a critical-sized mouse femur defect. The tissue engineered periosteum was evaluated for improving bone allograft healing and incorporation by locally delivering FGF-2, TGF-β1, and supporting ASCs transplantation. ASCs were successfully delivered and longitudinally tracked at the defect site for at least 7 days post operation with delivered FGF-2 and TGF-β1 showing a mitogenic effect on the ASCs. At 6 weeks post implantation, data showed a non-significant increase in normalized bone callus volume. However, union ratio analysis showed a significant inhibition in allograft incorporation, confirmed by histological analysis, due to loosening of the nanofiber coating from the allograft surface. Ultimately, this investigation shows our tissue engineered periosteum can deliver FGF-2, TGF-β1, and ASCs to a mouse critical-sized femur defect and further optimization may yield improved bone allograft healing.Entities:
Keywords: bone allograft; chitosan nanofibers; heparin-binding growth factors; mesenchymal stem cell; tissue-engineered periosteum
Mesh:
Substances:
Year: 2016 PMID: 27874253 DOI: 10.1002/jbm.a.35965
Source DB: PubMed Journal: J Biomed Mater Res A ISSN: 1549-3296 Impact factor: 4.396